These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34963694)

  • 21. HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry.
    Morsberger L; Pallavajjala A; Long P; Hardy M; Park R; Parish R; Nozari A; Zou YS
    Cancer Cell Int; 2022 Nov; 22(1):350. PubMed ID: 36376842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results.
    Geiersbach KB; Sill DR; Del Rosario KM; Meyer RG; Spears GM; Yuhas JA; Sukov WR; Jenkins RB; Ocal IT; Mounajjed T; Chen B
    Am J Clin Pathol; 2021 Oct; 156(5):886-894. PubMed ID: 33942843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
    Clauditz TS; Reiff M; Gravert L; Gnoss A; Tsourlakis MC; Münscher A; Sauter G; Bokemeyer C; Knecht R; Wilczak W
    Pathology; 2011 Aug; 43(5):459-64. PubMed ID: 21670724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
    Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
    Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L
    Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
    Press MF; Seoane JA; Curtis C; Quinaux E; Guzman R; Sauter G; Eiermann W; Mackey JR; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Bee V; Ma Y; Villalobos I; Slamon DJ
    JAMA Oncol; 2019 Mar; 5(3):366-375. PubMed ID: 30520947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers.
    Niu D; Li L; Yu Y; Zang W; Li Z; Zhou L; Jia L; Rao G; Gao L; Cheng G; Ji K; Lin D
    Pathol Oncol Res; 2020 Oct; 26(4):2577-2585. PubMed ID: 32621174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
    Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma.
    Kondo Y; Kikuchi T; Esteban JC; Kumaki N; Ogura G; Inomoto C; Hirabayashi K; Kajiwara H; Sakai A; Sugimoto R; Otsuru M; Okami K; Tsukinoki K; Nakamura N
    Pathol Int; 2014 Sep; 64(9):453-9. PubMed ID: 25209856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER2 Amplification by Next-Generation Sequencing in Lung Carcinoma: A Comparison of NGS Amplified and Non-amplified Cases by Immunohistochemistry and In Situ Hybridization.
    Kıvrak H; Özakıncı H; Karasoy D; Dizbay Sak S
    Balkan Med J; 2022 Jan; 39(1):21-29. PubMed ID: 34928234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.
    Catenacci DVT; Liao WL; Zhao L; Whitcomb E; Henderson L; O'Day E; Xu P; Thyparambil S; Krizman D; Bengali K; Uzzell J; Darfler M; Cecchi F; Blackler A; Bang YJ; Hart J; Xiao SY; Lee SM; Burrows J; Hembrough T
    Gastric Cancer; 2016 Oct; 19(4):1066-1079. PubMed ID: 26581548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.
    Forster-Sack M; Zoche M; Pestalozzi B; Witzel I; Schwarz EI; Herzig JJ; Fansa H; Tausch C; Ross J; Moch H; Varga Z
    J Pathol Clin Res; 2024 Mar; 10(2):e12362. PubMed ID: 38335502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
    Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
    Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™-HER2-FISH workflow.
    Grüntkemeier L; Khurana A; Bischoff FZ; Hoffmann O; Kimmig R; Moore M; Cotter P; Kasimir-Bauer S
    Breast Cancer; 2022 May; 29(3):487-497. PubMed ID: 35025065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
    Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
    Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
    Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria.
    Sun Q; Li Q; Gao F; Wu H; Fu Y; Yang J; Fan X; Cui X; Pu X
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):579-592. PubMed ID: 36018511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].
    Ying JM; Liu XY; Guo L; Xie YQ; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):296-300. PubMed ID: 22883666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Amplification and overexpression of HER-2/neu in parotid gland salivary duct carcinoma. Immunohistochemical study and fluorescence in situ hybridization].
    Skálová A; Stárek I; Vanĕcek T; Kucerová V; Plank L; Szépe P
    Cesk Patol; 2002; 38 Suppl 1():27-34. PubMed ID: 12677894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.